Universal Beteiligungs und Servicegesellschaft mbH Invests $2.34 Million in Certara, Inc. (NASDAQ:CERT)

Key Points

• Universal Beteiligungs und Servicegesellschaft mbH acquired 236,016 shares of Certara, Inc., valued at approximately $2.34 million, representing 0.15% ownership according to recent SEC filings.
• Analysts have a consensus target price of $15.29 for Certara, with ratings showing a mix of hold and buy opinions, while Barclays upgraded the stock to an "overweight" rating.
• Certara reported a quarterly EPS of $0.14, surpassing estimates, and experienced a 9.7% increase in revenue compared to the same quarter last year.

Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in Certara, Inc. (NASDAQ:CERT - Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 236,016 shares of the company's stock, valued at approximately $2,337,000. Universal Beteiligungs und Servicegesellschaft mbH owned about 0.15% of Certara at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Janney Montgomery Scott LLC purchased a new stake in Certara in the first quarter valued at approximately $120,000. First Trust Advisors LP purchased a new stake in Certara in the fourth quarter valued at approximately $140,000. Illinois Municipal Retirement Fund grew its holdings in Certara by 3.9% in the first quarter. Illinois Municipal Retirement Fund now owns 59,721 shares of the company's stock valued at $591,000 after purchasing an additional 2,268 shares during the period. Northern Trust Corp grew its holdings in Certara by 14.0% in the fourth quarter. Northern Trust Corp now owns 877,010 shares of the company's stock valued at $9,340,000 after purchasing an additional 108,038 shares during the period. Finally, Brown Advisory Inc. purchased a new stake in Certara in the first quarter valued at approximately $238,000. Institutional investors and hedge funds own 73.96% of the company's stock.

Wall Street Analyst Weigh In

Several research firms have issued reports on CERT. KeyCorp decreased their price objective on shares of Certara from $18.00 to $15.00 and set an "overweight" rating for the company in a research note on Monday, July 14th. JMP Securities reiterated a "market perform" rating on shares of Certara in a research note on Tuesday, May 6th. Barclays upgraded shares of Certara from an "equal weight" rating to an "overweight" rating and boosted their price objective for the stock from $11.00 to $14.00 in a research note on Thursday, May 8th. Robert W. Baird boosted their price objective on shares of Certara from $9.00 to $13.00 and gave the stock a "neutral" rating in a research note on Friday, April 11th. Finally, Morgan Stanley began coverage on shares of Certara in a research note on Thursday, July 3rd. They set an "equal weight" rating and a $16.00 price objective for the company. Four equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $15.29.

Certara Stock Down 3.0%

Shares of NASDAQ CERT traded down $0.30 during trading on Friday, reaching $9.54. 1,930,936 shares of the stock were exchanged, compared to its average volume of 1,485,978. The business's 50-day moving average price is $11.08 and its 200 day moving average price is $11.84. Certara, Inc. has a twelve month low of $8.64 and a twelve month high of $15.69. The company has a quick ratio of 2.78, a current ratio of 2.78 and a debt-to-equity ratio of 0.27. The company has a market capitalization of $1.55 billion, a price-to-earnings ratio of -477.00 and a beta of 1.42.

Certara (NASDAQ:CERT - Get Free Report) last posted its earnings results on Monday, May 5th. The company reported $0.14 EPS for the quarter, topping analysts' consensus estimates of $0.10 by $0.04. The business had revenue of $106.00 million for the quarter, compared to analysts' expectations of $104.44 million. Certara had a negative net margin of 0.67% and a positive return on equity of 5.05%. The business's revenue for the quarter was up 9.7% compared to the same quarter last year. During the same period in the previous year, the company posted $0.10 earnings per share. As a group, equities analysts forecast that Certara, Inc. will post 0.28 EPS for the current fiscal year.

Certara Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.